Physician profile

John A Walker

Family Medicine · Hammond, LA

NPI 1477536324

$7,131.12

in general payments reported to CMS, 2019-2025

43 companies · $216 in 2025

The $216 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,493.22

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $1,056.21 2019-2025 Trelegy Ellipta, Shingrix, Arexvy
Novo Nordisk INC $770.25 2019-2024 Ozempic, Rybelsus
Amgen INC. $758.03 2019-2024 Prolia, Evenity, Otezla
Takeda Pharmaceuticals U.S.A., INC. $564.08 2019-2024 Trintellix
Lilly USA, LLC $550.51 2019-2024 Mounjaro, Jardiance, Trulicity
Astrazeneca Pharmaceuticals Lp $487.33 2019-2025 Breztri, Fasenra, Farxiga
Abbvie INC. $358.12 2021-2025 Vraylar
Bayer Healthcare Pharmaceuticals INC. $303.02 2022-2024
Amarin Pharma, INC. $216.61 2019-2022
Janssen Pharmaceuticals, INC $200.40 2020-2023 Xarelto
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $199.11 2020-2025 Xifaxan
Pfizer INC. $174.51 2019-2024
Merck Sharp & Dohme LLC $152.42 2019-2023 Dificid
Boehringer Ingelheim Pharmaceuticals, INC. $127.75 2020-2023
Sanofi-Aventis U.S. LLC $111.35 2019-2020
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $99.73 2019-2023
Abbott Laboratories $92.04 2021-2024 Freestyle Libre
Biohaven Pharmaceuticals, INC. $79.40 2021
Eisai INC. $75.67 2020-2021
Boston Scientific Corporation $68.23 2022-2025 Ams 700
Teva Pharmaceuticals USA, INC. $61.18 2019-2021
Daiichi Sankyo INC. $53.60 2019
Biohaven Pharmaceutical Holding Company Ltd. $49.56 2022
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $46.12 2024-2025 Caplyta
Renalytix Ai, INC. $44.63 2023 Kidneyintelx Blood Collection Convenience Kit
Allergan, INC. $43.81 2020
Esperion Therapeutics, INC. $42.97 2021-2024 Nexletol
Radius Health, INC. $42.79 2020-2021
Tolmar, INC. $38.43 2024
Axsome Therapeutics, INC. $30.22 2024 Auvelity
Horizon Therapeutics Plc $29.59 2022-2023
Hikma Pharmaceuticals USA $22.26 2019
Indivior INC. $21.10 2024 Sublocade
Ironshore Pharmaceuticals INC. $20.26 2020
Astellas Pharma US INC $18.56 2020
Currax Pharmaceuticals LLC $17.81 2021
Tris Pharma INC $17.78 2024 Dyanavel Xr
Idorsia Pharmaceuticals US INC $15.50 2023 Quviviq
Avanir Pharmaceuticals, INC. $15.40 2019
Arbor Pharmaceuticals, INC. $14.80 2019
Paratek Pharmaceuticals, INC. $14.80 2022
Avion Pharmaceuticals $13.84 2020
Genentech USA, INC. $11.34 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John A Walker

$7,131.12

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $216 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/112440/john-a-walker

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.